Environmental risks of genetically engineered vaccines

Genetically Engineered Organisms: Assessing Environmental and Human Health Effects

Volumn , Issue , 2001, Pages 331-353

  Traavik, Terje ^a  

^a University of Tromsö   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056059015     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420042030     Document Type: Chapter

References (117)

1. Anderson, R. M., Rabies. Immunization in the field, Nature, 354, 502, 1991.
2. Anusz, Z. et al., Is Aujeszky’s disease a zoonosis? Przegl. Epidemiol., 46, 181, 1992.
3. Baba, T. W. et al., Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques, Nat. Med., 5, 194, 1999.
4. Bakker, E. et al., Germline mosaicism and Duchenne muscular dystrophy mutations, Nature, 329, 554, 1987.
5. Baxby, D. and Paoletti, E., Potential use of non-replicating vectors as recombinant vaccines, Vaccine, 10, 8, 1992.
6. Bergelson, J., Purrington, C. B., and Wichmann, G., Promiscuity in transgenic plants, Nature, 395, 25, 1998.
7. Benton, P. A. and Kennedy, R. C., DNA vaccine strategies for the treatment of cancer, Curr. Topics. Microbiol. Immunol., 226, 1, 1998.
8. Bett, A. J., Prevec, L., and Graham, F. L., Packaging capacity and stability of human adenovirus type 5 vectors, J. Virol., 67, 5911, 1993.
9. Blechynden, L. M. et al., Myositis induced by naked DNA immunization with the gene for histidyl-tRNA transferase, Hum. Gene Ther., 8, 1469-1480, 1997.
10. Block, W., Upton, C., and McFadden, G., Tumorigenic poxviruses: genomic organization of malignant rabbit virus, a recombinant between Shope fibroma virus and myxoma virus, Virology, 140, 113, 1985.
11. Bloom, B. R. and Widdus, R., Vaccine visions and their global impact, Nat. Med., 4, 480, 1998.
12. Bouma, A., De Jong, M. C., and Kimman, T. G., Transmission of two pseudorabies virus strains that differ in virulence and virus excretion in groups of vaccinated pigs, Am. J. Vet. Res., 57, 43, 1996.
13. Boyce, N., Suffer the children. The great taboo of gene therapy may have been broken, New Sci., 14, 7, 1998.
14. Bretscher, P. A. et al., Establishment of stable, cell-mediated immunity that makes “susceptible” mice resistant to Leishmania major, Science, 257, 539, 1992.
15. Brochier, B. et al., Large-scale eradication of rabies using recombinant vaccinia-rabies, Nature, 354, 520, 1991.
16. Brower, V., Naked DNA vaccines come of age, Nat. Biotechnol., 16, 1304, 1998.
17. Brown, P., Naked DNA raises cancer fears for researchers, New Sci., 128, 17, 1990.
18. Budker, V. et al., The efficient expression of intravenously delivered DNA in rat muscle, Gene Ther., 5, 272, 1998.
19. Cameron, J. and Abouchar, J., The precautionary principle, Boston Coll. Int. Comp. Law Rev., 14, 1, 1991.
20. Caravokyri, C., Pringle, C. R., and Leppard, K. N., Human adenovirus type 5 recombinants expressing simian immunodeficiency virus macaque strain gag antigens, J. Gen. Virol., 74, 2819, 1993.
21. Cheng, S. M. et al., Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant, J. Virol., 66, 6721, 1992.
22. Chévre, A. M. et al., Gene flow from transgenic crops, Nature, 389, 924, 1997.
23. Christensen, L. S. and Lomniczi, B., High frequency intergenomic recombination of suid herpesvirus 1 (SHV-1, Aujeszky’s disease), Arch. Virol., 132, 37, 1993.
24. Courvalin, P. et al., Gene transfer from bacteria to mammalian cells, C. R. Acad. Sci. III, 318, 1207, 1995.
25. Croce, C. M., Role of chromosome translocations in human neoplasia, Cell, 49, 155, 1987.
26. Danner, K., Acceptability of bio-engineered vaccines, Comp. Immunol. Microbiol. Infect. Dis., 20, 3, 1997.
27. Darji, A. et al., Oral somatic transgene vaccination using attenuated S. typhimurium, Cell, 91, 765, 1997.
28. Dellaire, G. and Chartrand, P., Direct evidence that transgene integration is random in murine cells, implying that naturally occurring double-strand breaks may be distributed similarly within the genome, Radiat. Res., 149, 325, 1998.
29. Doerfler, W. and Schubbert, R., Uptake of foreign DNA from the environment: the gastrointestinal tract and the placenta as portals of entry, Wien. Klin. Wochenschr., 110, 40, 1998.
30. Doerfler, W. et al., Integration of foreign DNA and its consequences in mammalian systems, Trends Biotechnol., 15, 297, 1997.
31. Donnelly, J. J. et al., DNA vaccines, Annu. Rev. Immunol., 15, 617, 1997.
32. Donnelly, J. J., Ulmer, J. B., and Liu, M. A., DNA vaccines, Dev. Biol. Stand., 95, 43, 1998.
33. Dumbell, K. and Richardson, M., Virological investigations of specimens from buffaloes affected by buffalopox in Maharashtra State, India between 1985 and 1987, Arch. Virol., 128, 257, 1993.
34. Ellis, R. W., New technologies for making vaccines, Vaccine, 17, 1596, 1999.
35. Fenner, F., Poxviruses, in Fields Virology, Vol. 2, 3rd ed., Fields, B. N. et al., Eds., Lippincott-Raven, Philadelphia, 1996, 2673.
36. Fenner F. et al., Smallpox and Its Eradication, World Health Organization, Geneva, 1988.
37. Fredriksen, K. et al., On the biological origin of anti-double-stranded (ds) DNA antibodies: systemic lupus erythematosus-related anti-dsDNA antibodies are induced by polyomavirus BK in lupusprone (NZBxNZW) F1 hybrids, but not in normal mice, Eur. J. Immunol., 24, 66, 1994.
38. Fries, L. F. et al., Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system, Vaccine, 14, 428, 1996.
39. Gershon, P. D. et al., Poxvirus genetic recombination during natural virus transmission, J. Gen. Virol., 70, 485, 1989.
40. Gorbunova, V. and Levy, A. A., Non-homologous DNA end joining in plant cells is associated with deletions and filler DNA insertions, Nucl. Acids Res., 25, 4650, 1997.
41. Greene, A. E. and Allison, R F., Recombination between viral RNA and transgenic plant transcripts, Science, 263, 1423, 1994.
42. Greene, A. E. and Allison, R. F., Deletions in the 3′untranslated region of cowpea chlorotic mottle virus transgene reduced recovery of recombinant viruses in transgenic plants, Virology, 225, 231, 1996.
43. Hanfman, D. T., The Status and Potential of Aquaculture in the United States: An Overview and Bibliography, U.S. Department of Agriculture, National Agricultural Library, Washington, D.C., 1993.
44. Hansen, H. et al., Comparison of thymidine kinase and A-type inclusion protein gene sequences from Norwegian and Swedish cowpox virus isolates, Acta Pathol. Microbiol. Scand., 107, 667, 1999.
45. Heinemann, J. and Roughan, P., New hypotheses on the material nature of horizontally mobile genes, Ann. N.Y. Acad. Sci., 906, 169, 2000.
46. Hengge, U. R., Walker, P. S. and Vogel, J. C., Expression of naked DNA in human, pig and mouse skin, J. Clin. Invest., 97, 2911, 1996.
47. Heppell, J. et al., Development of DNA vaccines for fish: vector design, intramuscular injection and antigen expression using viral haemorrhagic septicaemia virus genes as model, Fish Shellfish Immunol., 8, 271, 1998.
48. Hilleman, M. R., A simplified vaccinologists’ vaccinology and the pursuit of a vaccine against AIDS, Vaccine, 16, 778, 1998.
49. Ho, M.-W. et al., Gene technology and gene ecology of infectious diseases, Microb. Ecol. Health Dis., 10, 33, 1998.
50. Hoffman, S. L. et al., Toward clinical trials of DNA vaccines against malaria, Immunol. Cell Biol., 75, 376, 1997.
51. Jacobs, L., Glycoprotein E of pseudorabies virus and homologous proteins in other alphaherpesvirinae, Arch. Virol., 137, 209, 1994.
52. Jacobs, L. et al., Detection of wild-type Aujeszky’s disease virus by polymerase chain reaction in sheep vaccinated with a modified live vaccine strain, Res. Vet. Sci., 62, 271, 1997.
53. Jaffee, E. M., Immunotherapy of cancer, Ann. N.Y. Acad. Sci., 886, 67, 1999.
54. Jane, S. M., Cunningham, J. M., and Vanin, E. F., Vector development: a major obstacle in human gene therapy, Ann. Med., 30, 413, 1998.
55. Jenner, E., An inquiry into the causes and effects of the variolae vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of cow pox, London, 1798. Reprinted in Camac, C. N. B., Ed., Classics of Medicine and Surgery, Dover, New York, 1959, 213.
56. Jones, D. H. et al., Poly (DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration, Vaccine, 15, 814, 1997.
57. Jones, K. F., Bacterial vectors for vaccine delivery, in Designer Vaccines - Principles for Successful Prophylaxis, Hughes, H. P. A. and Campos, M., Eds., CRC Press, Boca Raton, FL, 1998, 151.
58. Kaplan, C., Vaccinia virus: a suitable vehicle for recombinant vaccines? Arch. Virol., 106, 127, 1989.
59. Khavari, P. A., Therapeutic gene delivery to the skin, Mol. Med. Today, 3, 533, 1997.
60. Kidwell, M. G., Lateral transfer in natural populations of eukaryotes, Annu. Rev. Genet., 27, 235, 1993.
61. Kimman, T. G., Acceptability of Aujeszky’s disease vaccines, Dev. Biol. Stand., 79, 129, 1992.
62. Kimman, T. G. et al., Aujeszky’s disease in horses fulfills Koch’s postulates, Vet. Rec., 128, 103, 1991.
63. Kipling, D. and Kearsey, S. E., Reversion of autonomously replicating sequence mutations in Saccharomyces cerevisiae: creation of a eucaryotic replication origin within procaryotic vector DNA, Mol. Cell. Biol., 10, 265, 1990.
64. Kit, S., Pseudorabies virus, in Encyclopedia of Virology, Webster, R. G. and Granoff, A., Eds., Academic Press, London, 1994, 1173.
65. Leong, J. C. and Fryer, J. L., Viral vaccines for aquaculture, Annu. Rev. Fish Dis., 3, 225, 1993.
66. Letvin, N. L., Progress in the development of an HIV-1 vaccine, Science, 280, 1875, 1998.
67. Liu, M. A., Vaccine developments, Nat. Med., 4, 515, 1998.
68. Lorenz, M. G. and Wackernagel, W., Bacterial gene transfer by natural genetic transformation in the environment, Microbiol. Rev., 58, 563, 1994.
69. Lorenzen, N. et al., Genetic vaccination of rainbow trout against viral haemorrhagic septicaemia virus: small amounts of plasmid DNA protect against a heterologous serotype, Virus Res., 63, 19, 1999.
70. Lowrie, D. B., DNA vaccination exploits normal biology, Nat. Med., 4, 147, 1998.
71. Lundgren, B. and DePierre, J. W., The metabolism of xenobiotics and its relationship to toxicity/genotoxicity: studies with human lymphocytes, Acta Physiol. Scand. Suppl., 592, 49, 1990.
72. Mandl, C. W. et al., In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model, Nat. Med., 4, 1438, 1998.
73. Mason, H. S., Lam, D. M., and Arntzen, C. J., Expression of hepatitis B surface antigen in transgenic plants, Proc. Natl. Acad. Sci. U.S.A., 89, 11745, 1992.
74. Mason, H. S. et al., Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene, Vaccine, 16, 1336, 1998.
75. McNally, R., Genetic madness. The European rabies eradication programme, Ecologist, 24, 207, 1994.
76. Mikkelsen, T. R., Anderson, B., and Bagger Jörgensen, R., The risk of crop transgene spread, Nature, 380, 31, 1996.
77. Miller, W. A. and Koev, G., Getting a handle on RNA virus recombination, Trends Microbiol., 6, 421, 1998.
78. Mor, T. S., Gomez-Lim, M. A., and Palmer, K. E., Perspective: edible vaccines - a concept coming of age, Trends Microbiol., 6, 449, 1998.
79. Moss, B., Poxviridae and their replication, in Fields Virology, Vol. 2, 3rd ed., Fields, B. N. et al., Eds., Lippincott-Raven, Philadelphia, 1996, 2637.
80. Mulder, W. A. M. et al., Pseudorabies virus infections in pigs. Role of viral proteins in virulence, pathogenesis and transmission, Vet. Res., 28, 1, 1997.
81. Myhr, A. I. and Traavik, T., The precautionary principle applied to deliberate release of genetically modified organisms (GMOs), Microb. Ecol. Health Dis., 11, 65, 1999.
82. Nagy, P. D. and Simon, A. E., New insights into the mechanisms of RNA recombination, Virology, 235, 1, 1997.
83. Nagy, P. D. et al., Dissecting RNA recombination in vitro: role of RNA sequences and the viral replicase, EMBO J., 17, 2392, 1998.
84. Nielsen, K. M. et al., Horizontal gene transfer from transgenic plants to terrestrial bacteria - a rare event? FEMS Microbiol. Rev., 22, 79, 1998.
85. Oger, P., Petit, A., and Dessaux, Y., Genetically engineered plants to terrestrial bacteria - a rare event? FEMS Microbiol. Rev., 22, 79, 1998.
86. Oslage, U. et al., Prevalence of antibodies against the viruses of European swine fever, Aujeszky’s disease and “porcine reproductive and respiratory syndrome” in wild boars in the federal states Sachsen-Anhalt and Brandenburg, Dtsch. Tierärtzl. Wochenschr., 101, 33, 1994.
87. Pastoret, P. P. et al., Stability of recombinant vaccinia-rabies vaccine in veterinary use, Dev. Biol. Stand., 87, 245, 1996.
88. Pensaert, M., et al., Round table on control of Aujeszky’s disease and vaccine development based on molecular biology, Vet. Microbiol., 33, 53, 1992.
89. Poppe, T. T. and Breck, O., Pathology of Atlantic Salmo salar intraperitoneally immunized with oil-adjuvated vaccine. A case report, Dis. Aquat. Organ., 29, 219, 1997.
90. Puman, L., Debate grows on safety of gene-therapy vectors, Lancet, 351, 808, 1998.
91. Raychaudhuri, S. and Rock, K. L., Fully mobilizing host defense: building better vaccines, Nat. Biotechnol., 16, 1025, 1998.
92. Sandvik, T. and Tryland, M., Orthopoxviruses in Norway, Ph.D. dissertation, University of Tromsö, 1996.
93. Sandvik, T. et al., Naturally occurring orthopoxviruses: potential for recombination with vaccine viruses, J. Clin. Microbiol., 36, 2542, 1998.
94. Schubbert, R. et al., Foreign (M13) DNA ingested by mice reaches peripheral leukocytes, spleen, and liver via the intestinal wall mucosa and can be covalently linked to mouse DNA, Proc. Natl. Acad. Sci. U.S.A., 94, 961, 1997.
95. Schwartz, A. R., Togo, Y., and Hornick, R. B., Clinical evaluation of live oral types 1, 2, and 5 adenovirus vaccines, Am. Rev. Respir. Dis., 109, 233, 1974.
96. Sheppard, M. and Boursnell, M., Viral vectors for viral vaccine delivery, in Designer Vaccines -Principles for Successful Prophylaxis, Hughes, H.P. A. and Campos, M., Eds., CRC Press, Boca Raton, FL, 1997, 125.
97. Sizemore, D. R., Branstrom, A. A., and Sadoff, J. C., Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization, Vaccine, 15, 804, 1997.
98. Spadafora, C., Sperm cells and foreign DNA: a controversial relation, BioEssays, 20, 955, 1998.
99. Standish, A., Enquist, L. W., and Schwaber, J. S., Innervation of the heart and its central medullary origin defined by viral tracing, Science, 263, 232, 1994.
100. Stegeman, J. A. et al., Intensive regional vaccination with a gI-deleted vaccine markedly reduces pseudorabies virus infections, Vaccine, 12, 527, 1994.
101. Strayer, D. S. et al., Malignant rabbit fibroma virus: observations on the culture and histopathologic characteristics of a new virus-induced rabbit tumor, J. Natl. Cancer Inst., 71, 91, 1983.
102. Tacket, C. O. et al., Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato, Nat. Med., 4, 607, 1998.
103. Taylor, J. and Paoletti, E., Fowlpox virus as a vector in non-avian species, Vaccine, 6, 466, 1988.
104. Taylor, J. et al., Efficacy studies on a canarypox-rabies recombinant virus, Vaccine, 9, 190, 1991.
105. Taylor, J. et al., Recombinant fowlpox virus inducing protective immunity in non-avian species, Vaccine, 6, 497, 1988.
106. Traavik, T., Too early may be too late, Report to the Directorate of Nature Management, Trondheim, Norway, 1999a.
107. Traavik, T., An orphan in science: environmental risks of genetically engineered vaccines, Report to the Directorate of Nature Management, Trondheim, Norway, 1999b.
108. Tryland, M. et al., Clinical cowpox cases in Norway, Scand. J. Infect. Dis., 30, 301, 1998a.
109. Tryland, M. et al., Characteristics of four cowpox virus isolates from Norway and Sweden, APMIS, 106, 623, 1998b.
110. Tryland, M. et al., Serosurvey for orthopoxviruses in rodents and shrews from Norway, J. Wildl. Dis., 34, 240, 1998c.
111. Tryland, M. et al., Antibodies against orthopoxviruses in wild carnivores from Fennoscandia, J. Wildl. Dis., 34, 443, 1998d.
112. Tryland, M. et al., Antibodies to orthopoxviruses in domestic cats in Norway, Vet. Rec., 143, 105, 1998e.
113. Tyler, K. L. and Fields, B. N., Pathogenesis of viral infections, in Fields Virology, Vol. 2, 3rd ed., Fields, B. N. et al., Eds., Lippincott-Raven, Philadelphia, 1996, 173.
114. Ulmer, J. B. et al., Heterologous protection against influenza by injection of DNA encoding a viral protein, Science, 259, 1745, 1993.
115. Vlassov, V. V., Balakireva, L. A., and Yakubov, L. A., Transport of oligonucleotides across natural and model membranes, Biochim. Biophys. Acta, 1197, 95, 1994.
116. Wolff, J. A. et al., Direct gene transfer into mouse muscle in vivo, Science, 247, 1465, 1990.
117. Zhang, G. et al., Expression of naked plasmid DNA injected into the afferent and efferent vessels of rodent and dog livers, Hum. Gene Ther., 8, 1763, 1997.